Plasma plasminogen activator inhibitor-1 level is not regulated by the hepatic low-density lipoprotein receptor-related protein [2]

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 11, 2007, Pages 2301-2304

  Hu, L ^a   Bovenschen, N ^b   Havekes, L M ^a,c   Van Vlijmen, B J M ^a   Tamsma, J T ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; COMPLEMENTARY DNA; LIVER PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN INHIBITOR; RECEPTOR ASSOCIATED PROTEIN; SERUM AMYLOID A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; HALF LIFE TIME; IN VIVO STUDY; LETTER; MOUSE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM;

ANIMALS; LDL-RECEPTOR RELATED PROTEIN 1; MICE; MICE, KNOCKOUT; PHARMACOKINETICS; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 35448995739     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02733.x     Document Type: Letter

References (13)

1. De Taeye B, Smith LH, Vaughan DE. Plasminogen activator inhibitor-1: A common denominator in obesity, diabetes and cardiovascular disease. Curr Opin Pharmacol 2005; 5: 149-54.
2. Anand SS, Yi Q, Gerstein H, Lonn E, Jacobs R, Vuksan V, Teo K, Davis B, Montague P, Yusuf S. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 2003; 108: 420-5.
3. Horn IR, van den Berg BM, Moestrup SK, Pannekoek H, van Zonneveld AJ. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator. Thromb Haemost 1998; 80: 822-8.
4. Hussain MM, Strickland DK, Bakillah A. The mammalian low-density lipoprotein receptor family. Annu Rev Nutr 1999; 19: 141-72.
5. Herz J, Strickland DK. LRP: A multifunctional scavenger and signaling receptor. J Clin Invest 2001; 108: 779-84.
6. Bovenschen N, Herz J, Grimbergen JM, Lenting PJ, Havekes LM, Mertens K, Van Vlijmen BJ. Elevated plasma factor VIII in a mouse model of low-density lipoprotein receptor-related protein deficiency. Blood 2003; 101: 3933-9.
7. Horn IR, van den Berg BM, van der Meijden PZ, Pannekoek H, van Zonneveld AJ. Molecular analysis of ligand binding to the second cluster of complement-type repeats of the low density lipoprotein receptor-related protein. Evidence for an allosteric component in receptor-associated protein-mediated inhibition of ligand binding. J Biol Chem 1997; 272: 13608-13.
8. Stefansson S, Kounnas MZ, Henkin J, Mallampalli RK, Chappell DA, Strickland DK, Argraves WS. gp330 on type II pneumocytes mediates endocytosis leading to degradation of pro-urokinase, plasminogen activator inhibitor-1 and urokinase-plasminogen activator inhibitor-1 complex. J Cell Sci 1995; 108 (Pt 6): 2361-8.
9. Degryse B, Neels JG, Czekay RP, Aertgeerts K, Kamikubo Y, Loskutoff DJ. The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1. J Biol Chem 2004; 279: 22595-604.
10. Rohlmann A, Gotthardt M, Hammer RE, Herz J. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J Clin Invest 1998; 101: 689-95.
11. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993; 92: 883-93.
12. Frykman PK, Brown MS, Yamamoto T, Goldstein JL, Herz J. Normal plasma lipoproteins and fertility in gene-targeted mice homozygous for a disruption in the gene encoding very low density lipoprotein receptor. Proc Natl Acad Sci U S A 1995; 92: 8453-7.
13. Biggs R, Bangham DR. Standardization of the one-stage prothrombin time test for the control of anticoagulant therapy: The availability and use of thromboplastin reference preparations. Am J Clin Pathol 1972; 57: 117-8.